Azenta (NASDAQ:AZTA) Stock Rated Hold in New Coverage at Zacks Research

Stock analysts at Zacks Research began coverage on shares of Azenta (NASDAQ:AZTA) in a report released on Thursday, Zacks reports. The brokerage set a “hold” rating on the stock.

AZTA has been the topic of a number of other research reports. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 26th. Needham & Company LLC lifted their price target on Azenta from $37.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen upgraded Azenta from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Jefferies Financial Group increased their price objective on Azenta from $44.00 to $52.00 and gave the company a “buy” rating in a research report on Wednesday. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $47.60.

Azenta Trading Up 4.1%

Shares of NASDAQ:AZTA traded up $1.79 during trading on Thursday, reaching $45.65. The company had a trading volume of 1,114,037 shares, compared to its average volume of 964,725. The company has a fifty day moving average of $36.52 and a two-hundred day moving average of $28.56. The stock has a market capitalization of $2.00 billion, a P/E ratio of -12.61 and a beta of 1.47. Azenta has a 12 month low of $15.93 and a 12 month high of $50.06.

Azenta (NASDAQ:AZTA) last posted its quarterly earnings data on Tuesday, November 10th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.17. Azenta had a negative net margin of 26.86% and a positive return on equity of 1.41%. The company had revenue of $167.09 million during the quarter, compared to the consensus estimate of $160.16 million. As a group, equities research analysts predict that Azenta will post 0.69 earnings per share for the current year.

Institutional Investors Weigh In On Azenta

A number of institutional investors have recently made changes to their positions in the business. Global Retirement Partners LLC boosted its stake in shares of Azenta by 82.3% in the 3rd quarter. Global Retirement Partners LLC now owns 771 shares of the company’s stock valued at $27,000 after purchasing an additional 348 shares in the last quarter. Heritage Family Offices LLP bought a new position in shares of Azenta during the 3rd quarter valued at $31,000. State of Wyoming purchased a new position in Azenta in the 1st quarter worth $38,000. Integrated Wealth Concepts LLC purchased a new position in Azenta in the 2nd quarter worth $39,000. Finally, Allworth Financial LP purchased a new position in Azenta in the 2nd quarter worth $48,000. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Latest Azenta News

Investors following AZTA have been watching these news items:

• Positive Sentiment: Better-than-expected quarterly results helped fuel buying: Azenta reported earnings of $0.28 per share versus analysts’ $0.11 estimate, and revenue of $167.1 million, above the $160.2 million consensus. Shares subsequently reached a 52-week high. Article: Azenta Reaches New 52-Week High Following Better-Than-Expected Earnings
• Positive Sentiment: Coverage highlighted commercial execution and new gene-synthesis capabilities as factors supporting Azenta’s outlook. KeyCorp’s estimates call for $0.69 EPS in FY2027 and $0.84 in FY2028; these are analyst forecasts, not company guidance. Article: Azenta Q3 Deep Dive
• Neutral Sentiment: After the sharp post-earnings advance, some investors took profits, contributing to a pullback; this may reflect near-term trading rather than a change in the company’s fundamentals. Article: Azenta Dips as Investors Book Profits

Azenta Company Profile

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.